Recombinant
RabMAb

Anti-Adipose Triglyceride Lipase antibody [EPR3444(2)] (HRP) (ab199197)

Overview

  • Product name
    Anti-Adipose Triglyceride Lipase antibody [EPR3444(2)] (HRP)
    See all Adipose Triglyceride Lipase primary antibodies
  • Description
    Rabbit monoclonal [EPR3444(2)] to Adipose Triglyceride Lipase (HRP)
  • Host species
    Rabbit
  • Conjugation
    HRP
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide within Human Adipose Triglyceride Lipase aa 350-450. The exact sequence is proprietary.

  • Positive control
    • WB: A431 Whole Cell and Human Skeletal Muscle tissue lysates.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab199197 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 54 kDa (predicted molecular weight: 55 kDa).

Target

  • Function
    Catalyzes the initial step in triglyceride hydrolysis in adipocyte and non-adipocyte lipid droplets. Also has acylglycerol transacylase activity. May act coordinately with LIPE/HLS within the lipolytic cascade. Regulates adiposome size and may be involved in the degradation of adiposomes. May play an important role in energy homeostasis. May play a role in the response of the organism to starvation, enhancing hydrolysis of triglycerides and providing free fatty acids to other tissues to be oxidized in situations of energy depletion.
  • Tissue specificity
    Highest expression in adipose tissue. Also detected in heart, skeletal muscle, and portions of the gastrointestinal tract. Detected in normal retina and retinoblastoma cells. Detected in retinal pigment epithelium and, at lower intensity, in the inner segments of photoreceptors and in the ganglion cell layer of the neural retina (at protein level).
  • Pathway
    Glycerolipid metabolism; triacylglycerol degradation.
  • Involvement in disease
    Note=Genetic variations in PNPLA2 may be associated with risk of diabetes mellitus type 2.
    Defects in PNPLA2 are the cause of neutral lipid storage disease with myopathy (NLSDM) [MIM:610717]; also known as neutral lipid storage disease without ichthyosis. NSLDM is a neutral lipid storage disorder (NLSD) with myopathy but without ichthyosis. NLSDs are characterized by the presence of triglyceride-containing cytoplasmic droplets in leukocytes and in other tissues, including bone marrow, skin, and muscle. Individuals with NLSDM did not show obesity, in spite of a defect in triglyceride degradation in fibroblasts and in marked triglyceride storage in liver, muscles, and other visceral cells.
  • Sequence similarities
    Contains 1 patatin domain.
  • Developmental stage
    Induced during differentiation of primary preadipocytes to adipocytes. Expression increased from fetal to adult in retinal pigment epithelium.
  • Cellular localization
    Lipid droplet. Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • 1110001C14Rik antibody
    • Adipose triglyceride lipase antibody
    • ATGL antibody
    • ATGL DESNUTRIN antibody
    • Calcium independent phospholipase A2 antibody
    • Calcium-independent phospholipase A2 antibody
    • Desnutrin antibody
    • EC 3.1.1.3 antibody
    • FP17548 antibody
    • IPLA2 zeta antibody
    • IPLA2-zeta antibody
    • Mutant patatin like phospholipase domain containing 2 antibody
    • Patatin like phospholipase domain containing 2 antibody
    • PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 2 antibody
    • Patatin-like phospholipase domain-containing protein 2 antibody
    • PEDF R antibody
    • PHOSPHOLIPASE A2 CALCIUM INDEPENDENT ZETA antibody
    • Pigment epithelium derived factor antibody
    • Pigment epithelium-derived factor antibody
    • plpl antibody
    • plpl2 antibody
    • PLPL2_HUMAN antibody
    • Pnpla2 antibody
    • Transport secretion protein 2 antibody
    • Transport secretion protein 2.2 antibody
    • Transport-secretion protein 2 antibody
    • Triglyceride hydrolase antibody
    • TTS 2.2 antibody
    • TTS2 antibody
    • TTS2.2 antibody
    • ZETA antibody
    see all

Images

  • All lanes : Anti-Adipose Triglyceride Lipase antibody [EPR3444(2)] (HRP) (ab199197) at 1/1000 dilution

    Lane 1 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 2 : Human skeletal muscle tissue lysate - total protein (ab29330)

    Lysates/proteins at 10 µg per lane.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 55 kDa
    Observed band size: 54 kDa (why is the actual band size different from the predicted?)


    Exposure time: 1 minute


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab199197 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab199197 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab199197.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up